Jupiter Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.3M Buy
238,980
+227,501
+1,982% +$14.3M 0.07% 283
2026
Q2
$657K Buy
+11,479
New +$629K ﹤0.01% 459
2021
Q4
– Sell
-23,471
Closed -$1.81M – 558
2021
Q3
$1.81M Buy
23,471
+13,598
+138% +$1.07M 0.02% 353
2021
Q2
$824K Buy
+9,873
New +$783K 0.01% 454
2021
Q1
– Sell
-5,416
Closed -$474K – 573
2020
Q4
$474K Buy
+5,416
New +$429K ﹤0.01% 513

Other funds holding BMRN

Jupiter Asset Management's BMRN Position: Q3 2026 in Review

Jupiter Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 1,982% in Q3 2026, buying an estimated $14.3M and bringing the position to 238,980 shares worth $14.3M. The position accounts for 0.07% of the portfolio, ranked #283.

Jupiter Asset Management first reported a position in BMRN in Q4 2020 and has held it in 5 quarters since. 434 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Jupiter Asset Management held 238,980 shares of BioMarin Pharmaceuticals worth $14.3M as of Q3 2026.
  • Jupiter Asset Management bought 227,501 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $14.3M.
  • BioMarin Pharmaceuticals made up 0.07% of Jupiter Asset Management's portfolio in Q3 2026, its #283 holding.
  • Jupiter Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
  • 434 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Jupiter Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.